In our cohort, TMB showed an inverse correlation with immune score in IDH-wildtype samples (R = −0.46, p = 0.03) (Figure 2C), and no correlation in IDH-mutant gliomas (Figure 2D), suggesting that the IDH mutation has an impact on the correlation of TMB and immune score. The gene discussed is IDH2; the disease is central nervous system cancer.